|Share.||Join the conversation||#HealthCloud|
NMTRC 2012 Symposium
Dell is hosting the annual symposium of the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), May 16–17 at Dell Children’s Medical Center in Austin. NMTRC’s extended team of biomedical researchers, pediatric oncologists, parents and advocates will be providing an update on the groundbreaking personalized medicine clinical trial that Dell is proudly supporting.
Join us to watch the Dell LiveStram Broadcast from the Dell Children's Hospital of Central Texas.
Courtesy of www.fittotweet.com
Fight Pediatric Cancer Day
In recognition of this important research endeavor and its ties to Central Texas, the cities of Austin and Round Rock have proclaimed May 16, 2012, as Fight Pediatric Cancer Day.
|Fight Pediatric Cancer Day — City of Austin Proclamation|
In conjunction with the NMTRC 2012 Symposium held at the Dell Children's Hospital of Central Texas and in recognition of Dell's ongoing efforts, Lee Leffingwell, Mayor of the City of Austin, Texas, has declared May, 16, 2012, as Fight Pediatric Cancer Day in Austin.
|Fight Pediatric Cancer Day — City of Round Rock Proclamation|
In conjunction with the NMTRC 2012 Symposium held at the Dell Children's Hospital of Central Texas and in recognition of Dell's ongoing efforts, Alan McGraw, Mayor of the City of Round Rock, Texas, has declared May, 16, 2012, as Fight Pediatric Cancer Day in Round Rock.
|Neuroblastoma — View the fact sheet|
Personalized medicine is offering new hope to neuroblastoma patients. The Neuroblastoma and Medulloblastoma Translational Research Consortium is conducting a first-of-its-kind genomic-based clinical trial to treat and study pediatric cancer — specifically relapsed and refractory neuroblastoma.
|Genomics and molecular medicine — View the fact sheet|
The increased understanding of molecular medicine is shifting clinical practice from treatment based on symptoms to treatment based on the underlying causes of disease. This will enable physicians to prescribe treatment plans that are designed more intelligently, work more effectively and have fewer toxic side effects.
|Cloud computing — View the fact sheet|
The cloud is the embodiment of a future-ready infrastructure that makes it possible to create a true healthcare "system." This ideal system — in which information is secure but accessible to those who need it — streamlines administration, enhances care quality and supports personalized medicine.
|For additional information visit these sites on Dell.com:|
Helping accelerate treatment for pediatric cancer with Dell cloud technology
Dell healthcare and life sciences
See how the Cloud is working to power advancement in fighting pediatric cancer.
The team of parents, genetic and translational medicine scientists and pediatric oncologists trailblazing personalized medicine in the treatment of deadly pediatric cancers is convening in Austin to discuss the status of the world’s first personalized medicine clinical trial for pediatric cancer and plan next steps at the NMTRC Symposium 2012. Neuroblastoma affects 1 in 100,000 children and is responsible for 1 in 7 pediatric cancer deaths.
Parents, advocates, oncologists from the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) and biomedical researchers from the Translational Genomics Research Institute (TGen), who are using high performance computing and cloud technology from Dell to identify targeted treatments based on the specific genetic vulnerabilities of each child’s tumor — an approach that could be used to treat all pediatric and adult cancers in the future.
Personalized medicine — treatment based on the specific vulnerabilities of each tumor — is overcoming longstanding barriers to treatment of pediatric cancer. There has been only one new treatment for pediatric cancer approved by the FDA since the 1980s, compared to 50 treatments approved for adult cancer in this same timeframe. As a result, pediatric oncologists use treatments designed for adults to treat children, with toxic side effects that are frequently as physically detrimental to the child as the cancer itself.
May 16, 1–2 pm CT
Keynote: "Molecular-Profiling for Optimized Precision Therapy"
|Dr. Timothy Triche |
University of Southern California/ Children’s Hospital Los Angeles
May 16, 2–4 pm CT
Panel Discussion: "Kids Cloud: Access to Data Boundaries"
|Dr. Melinda Merchant|
National Cancer Institute
|Dr. Gary Marchant|
Arizona State University
Kids V. Cancer Foundation
Friends of Will Foundation
Max’s Ring of Fire Foundation
|Dr. Giselle Sholler|
Van Andel Institute
|Dr. Spyro Mousses|
Translational Genomics Research Institute
|Dr. James Coffin|
Join us to watch the Dell LiveStream Broadcast of the event from Dell Children's Hospital in Austin, Texas.
Courtesy of Fittotweet: http://www.fittotweet.com/live/nmtrc/
Participate and join the conversation via the #HealthCloud hashtag on Twitter
|New Research Computing Cluster for Childhood Cancer Ready to Help Fast-Track Targeted Treatments|
The childhood cancer research computing cluster created and donated by Dell for the Translational Genomics Research Institute (TGen) is ready to support the world’s first precision medicine clinical trial for pediatric cancer.
|Dell Awards $100,000 Grant to Ronald McDonald House Charities for Work in 14 U.S. Cities|
Ronald McDonald House Charities has received a $100,000 Powering the Possible grant from Dell to support programs for families with children undergoing pediatric cancer treatment.
|Innovators in Pediatric Cancer to Share Progress on Groundbreaking Personalized Medicine Clinical Trial|
Dell to host NMTRC Symposium 2012, annual meeting of biomedical researchers, pediatric oncologists, parents and advocates.
|Computerworld Recognizes Dell for Support of Childhood Cancer Research |
IDG’s Computerworld Honors Program has recognized Dell as a 2012 Laureate for its commitment in support of childhood cancer care research globally.
|Dell Commits Funding, Cloud Technology and Employee Engagement to Fight Neuroblastoma and Other Pediatric Cancers|
Dell launches new multimillion dollar, multiyear commitment to pediatric cancer as expansion of company’s overall philanthropic program — Dell Powering the Possible.
|Powering the Possible for Those Battling Pediatric Cancer|
Today we announced the expansion of our giving efforts, Powering the Possible, to help fight pediatric cancer. And I’m really proud of this new extension.
|Karen Quintos||Dr. Jeff Trent||Dr. Jeff Trent|
|"Finding a treatment for this disease is so important to Dell's leadership team"||"Thank you to Dell"||"What you'll hear during the Symposium"|
View Highlights on Flickr from the Keynote at the NMTRC 2012 Symposium from Dell
Children's Hospital of Central Texas on May 16, 2012.
View the video archive of Dell's November 10th press briefing by clicking on the
NMRTC Symposium 2012
|Do you know a child with neuroblastoma?|
Dell is proud to support the world's first personalized medicine trial for pediatric cancer conducted by the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) at VARI and supported by the Translational Genomics Research Institute. NMTRC is a group of 11 universities and children's hospitals offering a nationwide network of childhood cancer clinical trials.
To learn more about enrolling a child in this or other NMTRC clinical trials, please visit NMTRC's Web site or contact Genevieve Bergendahl at +1 616-234-5707